Fasudil Hydrochloride Injection

Fasudil Hydrochloride Injection inhibits the phosphorylation of myosin light chains in the final stage of smooth muscle contraction, leading to vasodilation. It has demonstrated relief and prevention of cerebral vasospasm in dogs through two intracranial injections of autologous blood, and intravenous administration of fasudil hydrochloride can alleviate cerebral vasospasm. Early continuous administration can prevent the occurrence of cerebral vasospasm. It improves cerebral cortical blood flow in a delayed cerebral vasospasm model in dogs. In a rat model of cerebral ischemia induced by bilateral carotid artery occlusion, it increases local cerebral blood flow in the ischemic region. In patients with decreased cerebral blood flow, positron emission tomography (PET) has shown an increase in blood flow in the ischemic region. It also partially increases brain regional glucose utilization in a rat model of cerebral ischemia induced by bilateral carotid artery occlusion. It exhibits inhibitory effects on delayed neuronal cell damage in a sand rat model of cerebral ischemia induced by transient bilateral carotid artery occlusion. The mechanism of action (in vitro experiments) involves inducing relaxation of isolated cerebral blood vessels. It inhibits the vasoconstrictive effect caused by calcium ions in isolated blood vessels. It inhibits vasoconstriction caused by various cerebral vasoconstrictive agents. It inhibits the phosphorylation of myosin light chains during vascular constriction without reducing intracellular calcium levels. It also inhibits myosin light chain phosphorylation enzymes under conditions similar to those in the body.

Packaging： 60 boxes per case

Specifications： 2ml:30mg

Shelf Life：

Approval Number：

Indications： Improvement and prevention of cerebral vasospasm and resulting cerebral ischemic symptoms after subarachnoid hemorrhage surgery.